Microphthalmia-associated transcription factor controls the DNA damage response and a lineage-specific senescence program in melanomas.

Apoptosis and senescence are cellular failsafe programs that counteract excessive mitogenic signaling observed in cancer cells. Melanoma is known for its notorious resistance to apoptotic processes; therefore, senescence, which remains poorly understood in melanomas, can be viewed as a therapeutic alternative. Microphthalmia-associated transcription factor (MITF), in which its M transcript is specifically expressed in melanocyte cells, plays a critical role in melanoma proliferation, and its specific inhibition is associated with G(0)-G(1) growth arrest. Interestingly, decreased MITF expression has been described in senescent melanocytes, and we have observed an inhibition of MITF expression in melanoma cells exposed to chemotherapeutic drugs that induce their senescence. All these observations thereby question the role of MITF in controlling senescence in melanoma cells. Here, we report that long-term depletion of MITF in melanoma cells triggers a senescence program characterized by typical morphologic and biochemical changes associated with a sustained growth arrest. Further, we show that MITF-silenced cells engage a DNA damage response (DDR) signaling pathway, leading to p53 upregulation, which is critically required for senescence entry. This study uncovers the existence of a lineage-restricted DDR/p53 signaling pathway that is inhibited by MITF to prevent senescence and favor melanoma cell proliferation.

[1]  Alexandra Eitel.  Senescence , 2014, British medical journal.

[2]  P. Foubert,et al.  Integrin α4β1 signaling is required for lymphangiogenesis and tumor metastasis (Cancer Research (2010) 70, (3042-51) DOI , 2010 .

[3]  W. Lu,et al.  Tumor site-specific silencing of NF-κB p65 by targeted hollow gold nanosphere-mediated photothermal transfection (Cancer Research (2010) 70, (3177-3188) DOI: 10.1158/0008-5472.CAN-09-3379) , 2010 .

[4]  R. Hoffman,et al.  The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms. , 2010, Cancer research.

[5]  T. Schall,et al.  Tumor and Stem Cell Biology Cancer Research The Chemokine Receptor CXCR 7 Is Highly Expressed in Human Glioma Cells and Mediates Antiapoptotic Effects , 2010 .

[6]  Chris T. Harvey,et al.  ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21. , 2010, Cancer research.

[7]  Jing Ma,et al.  Immunohistochemical expression of BRCA1 and lethal prostate cancer. , 2010, Cancer research.

[8]  J. F. Burrows,et al.  The deubiquitinating enzyme USP17 is highly expressed in tumor biopsies, is cell cycle regulated, and is required for G1-S progression. , 2010, Cancer research.

[9]  C. Croce,et al.  Oncogenic role of miR-483-3p at the IGF2/483 locus. , 2010, Cancer research.

[10]  G. Mills,et al.  Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. , 2010, Cancer research.

[11]  J. Heath,et al.  Signal transducers and activators of transcription-3 binding to the fibroblast growth factor receptor is activated by receptor amplification. , 2010, Cancer research.

[12]  M. Kloor,et al.  Somatic hypermethylation of MSH2 is a frequent event in Lynch Syndrome colorectal cancers. , 2010, Cancer research.

[13]  J. Vincent,et al.  5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. , 2010, Cancer research.

[14]  P. Fisher,et al.  Molecular mechanism of chemoresistance by astrocyte elevated gene-1. , 2010, Cancer research.

[15]  A. Muotri,et al.  Coordination of centrosome homeostasis and DNA repair is intact in MCF-7 and disrupted in MDA-MB 231 breast cancer cells. , 2010, Cancer research.

[16]  H. Kung,et al.  Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. , 2010, Cancer research.

[17]  J. Chien,et al.  Downregulation of HtrA1 promotes resistance to anoikis and peritoneal dissemination of ovarian cancer cells. , 2010, Cancer research.

[18]  Wei Lu,et al.  Tumor Site–Specific Silencing ofNF-κB p65by Targeted Hollow Gold Nanosphere–Mediated Photothermal Transfection , 2010, Cancer Research.

[19]  C. Bertolotto,et al.  Fifteen‐year quest for microphthalmia‐associated transcription factor target genes , 2010, Pigment cell & melanoma research.

[20]  T. Saida,et al.  Simultaneous suppression of MITF and BRAFV600E enhanced inhibition of melanoma cell proliferation , 2009, Cancer science.

[21]  D. Elder,et al.  The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes. , 2009, The American journal of pathology.

[22]  L. Zou,et al.  Single-stranded DNA orchestrates an ATM-to-ATR switch at DNA breaks. , 2009, Molecular cell.

[23]  Michael Krauthammer,et al.  Integrative Analysis of Epigenetic Modulation in Melanoma Cell Response to Decitabine: Clinical Implications , 2009, PloS one.

[24]  T. Giordano,et al.  C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells , 2008, Oncogene.

[25]  Z. Darżynkiewicz,et al.  Phosphorylation of p53 on Ser15 during cell cycle and caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation , 2008, Cell cycle.

[26]  L. Poling,et al.  Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage , 2008, Pigment cell & melanoma research.

[27]  C. Blattner,et al.  p53 stabilization in response to DNA damage requires Akt/PKB and DNA-PK , 2008, Proceedings of the National Academy of Sciences.

[28]  K. Bille,et al.  IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin. , 2008, The Journal of investigative dermatology.

[29]  J. Zha,et al.  Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas. , 2008, Cancer research.

[30]  J. Bartek,et al.  DNA damage signalling guards against activated oncogenes and tumour progression , 2007, Oncogene.

[31]  Dean W. Felsher,et al.  Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation , 2007, Proceedings of the National Academy of Sciences.

[32]  E. Medrano,et al.  Dynamic assembly of chromatin complexes during cellular senescence: implications for the growth arrest of human melanocytic nevi , 2007, Aging cell.

[33]  W. Saunders,et al.  DNA repair pathways involved in anaphase bridge formation , 2007, Genes, chromosomes & cancer.

[34]  T. Kishida,et al.  Therapeutic RNA interference of malignant melanoma by electrotransfer of small interfering RNA targeting Mitf , 2007, Gene Therapy.

[35]  Jane Goodall,et al.  Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. , 2006, Genes & development.

[36]  R. Marais,et al.  Cellular senescence in naevi and immortalisation in melanoma: a role for p16? , 2006, British Journal of Cancer.

[37]  R. Bernards,et al.  Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence , 2006, Nature Cell Biology.

[38]  Weili Ma,et al.  p53-Dependent Transcriptional Repression of c-myc Is Required for G1 Cell Cycle Arrest , 2005, Molecular and Cellular Biology.

[39]  M. Khaled,et al.  The cleavage of microphthalmia-associated transcription factor, MITF, by caspases plays an essential role in melanocyte and melanoma cell apoptosis. , 2005, Genes & development.

[40]  T. Golub,et al.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.

[41]  J. Folkman,et al.  CDK2 translational down-regulation during endothelial senescence. , 2005, Experimental cell research.

[42]  P. Khavari,et al.  Use of human tissue to assess the oncogenic activity of melanoma-associated mutations , 2005, Nature Genetics.

[43]  E. Medrano,et al.  Dynamic regulation of the human dopachrome tautomerase promoter by MITF, ER-alpha and chromatin remodelers during proliferation and senescence of human melanocytes. , 2005, Pigment cell research.

[44]  R. Weinberg,et al.  The signals and pathways activating cellular senescence. , 2005, The international journal of biochemistry & cell biology.

[45]  D. Stern,et al.  Regulation of CHK2 by DNA-dependent Protein Kinase* , 2005, Journal of Biological Chemistry.

[46]  L. Larue,et al.  Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression , 2005, Nature.

[47]  L. Ventéo,et al.  In vivo overexpression of tumstatin domains by tumor cells inhibits their invasive properties in a mouse melanoma model. , 2004, Experimental cell research.

[48]  T. Golub,et al.  Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. , 2004, Cancer cell.

[49]  Mathew J Garnett,et al.  Guilty as charged: B-RAF is a human oncogene. , 2004, Cancer cell.

[50]  M. Khaled,et al.  PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes , 2004, Cell Death and Differentiation.

[51]  Keith W. Vance,et al.  Tbx2 Directly Represses the Expression of the p21WAF1 Cyclin-Dependent Kinase Inhibitor , 2004, Cancer Research.

[52]  M. Khaled,et al.  Microphthalmia associated transcription factor is a target of the phosphatidylinositol-3-kinase pathway. , 2003, The Journal of investigative dermatology.

[53]  N. Curtin,et al.  Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. , 2003, Cancer research.

[54]  S. Lowe,et al.  Rb-Mediated Heterochromatin Formation and Silencing of E2F Target Genes during Cellular Senescence , 2003, Cell.

[55]  S. Lowe,et al.  Apoptosis and melanoma chemoresistance , 2003, Oncogene.

[56]  Junjie Chen,et al.  p53 Binding Protein 53BP1 Is Required for DNA Damage Responses and Tumor Suppression in Mice , 2003, Molecular and Cellular Biology.

[57]  Sridhar Ramaswamy,et al.  Bcl2 Regulation by the Melanocyte Master Regulator Mitf Modulates Lineage Survival and Melanoma Cell Viability , 2002, Cell.

[58]  L. Chin,et al.  Dual Inactivation of RB and p53 Pathways in RAS-Induced Melanomas , 2001, Molecular and Cellular Biology.

[59]  J. Harbour,et al.  Deregulation of the Rb and p53 pathways in uveal melanoma. , 2000, American Journal of Pathology.

[60]  E. Lam,et al.  Inhibition of the Phosphoinositide 3-Kinase Pathway Induces a Senescence-like Arrest Mediated by p27Kip1 * , 2000, The Journal of Biological Chemistry.

[61]  S. Jackson,et al.  Regulation of p53 in response to DNA damage , 1999, Oncogene.

[62]  M. Haugg,et al.  p27Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells , 1999, Oncogene.

[63]  D. Fisher,et al.  Microphthalmia Gene Product as a Signal Transducer in cAMP-Induced Differentiation of Melanocytes , 1998, The Journal of cell biology.

[64]  E. Rogakou,et al.  DNA Double-stranded Breaks Induce Histone H2AX Phosphorylation on Serine 139* , 1998, The Journal of Biological Chemistry.

[65]  Hong Wang,et al.  Prognostic implications of p53 overexpression in cutaneous melanoma from sun‐exposed and nonexposed sites , 1998, Cancer.

[66]  A. Copeta,et al.  Urokinase-type and tissue-type plasminogen activators as growth factors of human fibroblasts. , 1994, Experimental cell research.

[67]  J. F. Burrows,et al.  Tumor and Stem Cell Biology Cancer Research The Deubiquitinating Enzyme USP 17 Is Highly Expressed in Tumor Biopsies , Is Cell Cycle Regulated , and Is Required for G 1S Progression , 2010 .

[68]  J. Chien,et al.  Downregulation of HtrA 1 Promotes Resistance to Anoikis and Peritoneal Dissemination of Ovarian Cancer Cells , 2010 .

[69]  Myriam Alcalay,et al.  Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells , 2009, Nature.

[70]  Frédérick A. Mallette,et al.  The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. , 2007, Genes & development.

[71]  H. Gaylord,et al.  AMERICAN ASSOCIATION FOR CANCER RESEARCH. , 1913, California state journal of medicine.